Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Inducible Mechanisms for Hepatotoxicity caused by Traditional Korean Medicines in a View of Toxicology

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2011, v.32 no.4, pp.48-67



  • Downloaded
  • Viewed

Abstract

Objectives: There has been a lot of controversy about whether Korean traditional medicines cause drug-induced hepatotoxicity or not. However, this controversy has not been examined from a scientific approach, especially in terms of toxicology. Thus, this article for traditional Korean medicine-induced hepatotoxicity was reviewed on a basis of toxicological assessment. Methods: Toxicological assessments were carried out in a view of reactive intermediates formation from biotransformation in animals based on cytochrome P450 activity inducing oxidative stress, and case reports in world-wide. Results and Conclusions: Several herbal materials used for traditional Korean medicines were identified as possible agents causing drug-induced hepatotoxicity. Most of these agents seem to produce toxic reactive intermediates caused by cytochrome P450. Oxidative stress followed by cytochrome P450 activation could also be a reason for herb-induced hepatotoxicity. Plausible prevention of herb-induced hepatotoxicity was suggested.

keywords
traditional Korean medicines, hepatotoxicity, cytochrome P450, oxidative stress, toxicology


Reference

1

1. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997. J Am Med Assoc. 1998;280:1569- 1575.

2

2. Stricker B. Drug-induced Hepatic Injury. 2nd edn. Amsterdam: Elsevier; 1992:25-35.

3

3. Jean-Pastor MJ, Bilan J. des accidents htpatiques medicamenteux recueillis par la pharmacovigilance fransaise. Therapie, 1984;39:493-500.

4

4. Dossing M, Andreasen BP. Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish board of adverse reaction to drugs. Stand J Gastroenter. 1982;17:205511.

5

5. 식품의약품안전청, 한약 간독성보고서, 2005;20- 40.

6

6. Dominique L, Hepatotoxicity of herbal remedies, Journal of Hepatology. 1997;26(Suppl. 1):47-51.

7

7. Parola M, Robino G, Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001;35: 297-306.

8

8. Fujita K, Kamataki T. Genetically engineered bacterial cells co-expressing human cytochrome P450 with NADPH cytochrome P450 reductase: prediction of metabolism and toxicity of drugs in humans. Drug Metab Pharmacokinet. 2002;17: 1-22.

9

9. Lynch T, Price A. “The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects”. American Family Physician. 2007;76(3):391-6.

10

10. Ajay K, Vetel Yl, Ashok P, Bhosle P, Ingawale D. Drug Induced Hepatotoxicity: A Comprehensive Review, The Internet Journal of Pharmacology. 2010;8(2):313-328.

11

11. Tarantino G, Minno D, Capone D. Drug-induced liver injury: Is it somehow foreseeable? World J Gastroenterol. 2009;15(23):2817-2833.

12

12. Pessayre D, Larrey D, Biour M. Drug-induced liver injury. In: Bircher J, Benhamou JP, McIntyre N, Rizzetto M, Rod& J, editors. Oxford Textbook of Clinical Hepatology, 2nd edn, Vol. 2. Oxford University Press, 1999:1261-315.

13

13. 박영철. 독성학의 분자-생화학적 원리. 한국학술 정보(주), 2010;40-45.

14

14. Beaune PH, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-endoplasmic reticulum auto-antibodies appearing in a druginduced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Nat Acad Sci USA, 1987;84:551-5.

15

15. Whiting PW, Clouston A, Kerlin P. Black cohosh and other.herbal remedies associated with acute hepatitis. Med J Aust. 2002;177:440-443.

16

16. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatol. 2003; 37:924-930.

17

17. 서정철, 전원중, 박성순, 김석형, 이기만, 채희복, et al. 급성 독성간염 48예의 임상 경험, 대한간학 회지, 2006;12(1):74-81.

18

18. Marti L, Del Olmo JA, Tosca J, Ornia E, Garcia-Torres ML, Serra MA, et al. Clinical evaluation of drug-induced hepatitis. Rev Esp Enferm Dig. 2005;97:258-265.

19

19. Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26: 664-69.

20

20. Takahashi Y, Okuda K. Fulminant hepatitis in Japan: etiology and prognostic prediction, Chin J Gastroenterol. 1993;10:337-350.

21

21. Dansette PM, Bonierbale E, Minoletti C, Beaune PH, Pessayre D, Mansuy D. Drug-induced immunotoxicity. Eur J Drug Metab Pharmacokinet. 1998;23:443-51.

22

22. Melchart, D, Linde, jS, Hager, zJ, Kaesmayr, TD, Shaw, R, Bauer, W, et al. Monitoring of liver enzymes in patients treated with traditional Chinese drugs. JAMA. 1999; 282:28-29.

23

23. Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez F, et al. Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity, Toxicology and Applied Pharmacology. 2008;228:295-300.

24

24. Fu PP, Xia QS, Lin G, Chou MW. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev. 2004;36:1-55.

25

25. Mattocks AR. Chemistry and toxicology of pyrrolizidine alkaloids. London Academic Press, 1986.

26

26. Prakash S, Pereira T, Paul E. Seawright A. Pyrrolizidine alkaloids in human diet Arungundrum Mutation Research. 1999;443:53-67.

27

27. Petry TW, Bowden GT, Huxtable RJ, Sipes IG. Characterization of hepatic DNA damage induced in rats by the pyrrolizidine alkaloid monocrotaline. Cancer Res. 1984;44:1505-1509.

28

28. Yan CC and Huxtable RJ. Effects of Monocrotaline, Pyrrolizidine Alkaloid on Glutathione Metabolism in the Rat, Biochemical Pharmacology, 1996; 51:375-379.

29

29. Copple B, Ganey P, Liver inflammation during monocrotaline hepatotoxicity Toxicology. 2003; 190:155-169.

30

30. 안병민, 생약재에 의한 간독성, 대한의사협회지, 2007;특집:318-324.

31

31. Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, syo-saiko-to(xiao-chai-hu-tang). Dig Dis Sci.1995;40:1845-1848.

32

32. Hsu L, Huang Y, Tsay S, Chang F, Lee S. Acute Hepatitis Induced by Chinese Hepatoprotective H Xiao-Chai-Hu-Tangerb, J Chin Med Assoc. 2006;69(2):86-88.

33

33. Kiguchi T, Kimura F, Niiya K, Katayama Y, Harada M. Acute hrombocytopenic purpura after ingestion of Sho-saiko-to for hepatitis. Liver. 2000;20:491.

34

34. Haouzi D, Lekehal M, Moreau A, Moulis C, Feldmann G, Robin MA, et al. Cytochrome P450-generated reactive metabolites cause mitochondrial permeability transition, caspase activation, and apoptosis in rat hepatocyte. Hepatology 2000;32:303-311.

35

35. Richard T. Tovar, MD. Herbal Toxicity Diseasea- Month, 2009;55(10):592-641.

36

36. Stickel F, Patsenker E, Schuppan D, Herbal hepatotoxicity. Journal of Hepatology. 2005;43: 901-910.

37

37. Vassiliadis, T, Anagnostis P, Patsiaoura K, Giouleme O, Katsinelos P, Mpoumponaris A, et al. Letters to the Editor: Valeriana hepatotoxicity, Sleep Medicine. 2009;10:935-936.

38

38. Report of an International Consensus Meeting. Criteria of druginduced liver disorders. J Hepatol. 1990;11:272-276.

상단으로 이동

Journal of Korean Medicine